Summary: Loss of smell and taste causes emotional, social, and psychological harm on a scale comparable to some of the world’s most serious chronic illnesses. A comprehensive review of clinical evidence measured quality-of-life metrics across many long-term conditions and found that chemosensory disorders carry a far larger burden than commonly assumed.
Contrary to the widespread belief that smell and taste loss are minor inconveniences, the review reveals substantial suffering experienced by millions. Patients report high rates of clinical depression, ongoing social isolation, disrupted nutrition, and persistent anxiety tied to their sensory loss.
Key Facts
- Chronic illness equivalence: Standardized quality-of-life measures for people with smell and taste disorders (SATDs) often match or are worse than scores for patients with diabetes, stroke, heart failure, and Parkinson’s disease.
- Psychological burden: Without chemosensory input, many describe emotional numbness, social withdrawal, and high, recurrent levels of clinical depression.
- Nutritional disruption: Eating can shift from pleasure to pure function, leading to significant weight loss in some and weight gain in others who seek intensely flavored foods to compensate.
- Safety and anxiety: The inability to detect smoke, gas, or spoiled food produces chronic safety concerns and heightened survival anxiety.
- Systemic neglect: Despite strong evidence of harm, healthcare systems frequently treat these disorders as temporary or minor, resulting in limited diagnostics, few specialist clinics, and scarce validated treatments.
Source: University of East Anglia
University of East Anglia research shows that smell loss can affect quality of life as severely as conditions including diabetes, stroke, Parkinson’s, and kidney failure.
For millions, the ability to smell a morning coffee or taste a home-cooked meal is taken for granted. When those senses disappear, everyday life often becomes bleak: patients report levels of distress comparable to many life-altering chronic illnesses.
The findings overturn the common misconception that losing smell or taste is only a minor nuisance. Experts warn the condition is frequently underestimated and insufficiently treated.
How the research was carried out
Researchers conducted a narrative review of years of medical evidence, synthesizing data from dozens of studies that compared quality-of-life scores across a broad spectrum of chronic conditions, including diabetes, stroke, heart failure, asthma, and other cardiovascular and respiratory disorders.
Lead researcher Professor Carl Philpott from the Norwich Medical School at the University of East Anglia explained that smell and taste disorders consistently produce significant emotional, social, and psychological harm that can rival widely recognised long-term illnesses. Patients reported loss of pleasure in food, difficulties socialising, anxiety about personal safety, and pervasive emotional numbness. Depression and social withdrawal were commonly reported across studies.
Food as fuel and pleasure
Smell contributes most of what we perceive as taste. When olfactory function is lost, meals can become bland, metallic, or even repulsive. For many, eating ceases to be pleasurable and becomes merely a way to fuel the body. The review documents two common nutritional trajectories: some people lose appetite and experience dangerous weight loss; others overcompensate by seeking intensely sweet, salty, or processed foods and gain weight.
This sensory loss disrupts family meals, celebrations, and social rituals, eroding everyday pleasures and social connection.
Healthcare gaps and the legacy of COVID-19
Despite the severe effects, healthcare systems often downplay persistent chemosensory disorders as temporary or inconsequential. Specialist services are scarce, diagnostic pathways are limited, and access to validated therapies is tightly constrained. The COVID-19 pandemic brought anosmia (loss of smell) and ageusia (loss of taste) into public awareness, with many patients recovering but others left with permanent or distorted perceptions such as parosmia, where common smells become nauseating. The pandemic highlighted an existing problem that medicine has been slow to address.
The authors call for better recognition, investment in specialist clinics, and more research into treatments—not as a matter of comfort alone, but as an urgent public-health and wellbeing priority.
Comparing Quality of Life in Smell and Taste Disorders With Other Chronic Conditions—A Narrative Review is published in the journal Clinical Otolaryngology.
Key Questions Answered
A: The olfactory system connects directly to brain regions that govern emotion and memory—the olfactory bulb projects to the amygdala and hippocampus. When that pathway is disrupted, people lose an important anchor for emotional memory, situational context, and reward processing, which can generate a distinct form of emotional numbness and contribute to depression.
A: Because smell accounts for most flavor perception, its loss reduces the sensory reward of eating. Some individuals avoid food and lose weight, while others seek out highly palatable, processed, or intensely flavored items, leading to unhealthy weight gain. Both extremes pose metabolic and health risks.
A: The review highlights systemic neglect: clinicians often minimise persistent sensory loss, diagnostic services are limited, few specialist clinics exist, and validated therapeutic options remain scarce. This leaves many people managing a chronic, life-altering condition with little support.
Editorial Notes
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by the editorial team.
- Additional context was added by the staff to clarify clinical implications and patient impact.
About this research and reporting
Author: Lisa Horton
Source: University of East Anglia
Contact: Lisa Horton – University of East Anglia
Image: Image credited to Neuroscience News
Original Research: Open access. “Comparing Quality of Life in Smell and Taste Disorders With Other Chronic Conditions—A Narrative Review” by Natalia Glibbery, David Turner, Duncan Boak, Carl Philpott. Clinical Otolaryngology. DOI: 10.1111/coa.70119
Abstract
Comparing Quality of Life in Smell and Taste Disorders With Other Chronic Conditions—A Narrative Review
Objectives
Smell and taste disorders (SATDs) are increasingly common but remain underrecognised, with substantial effects on physical, social, and psychological wellbeing. Building on prior cohort work reporting Olfactory Disorder Questionnaire (ODQ), EQ-5D-5L, and EQ-5D-5L VAS scores for patients with SATDs, this review evaluates the disease burden of SATDs by comparing established quality-of-life and depression metrics against those reported for other chronic conditions.
Methods
A literature review covered publications from 1 January 2010 to 10 August 2024 to identify systematic reviews and studies reporting EQ-5D-5L or Beck Depression Inventory (BDI) values across chronic conditions.
Results
EQ-5D-5L and BDI scores for patients with SATDs were found to be comparable to scores reported for diabetes, stroke, cardiovascular, respiratory, and other long-term ENT disorders, demonstrating a substantial and often underestimated burden on quality of life.
Conclusion
Olfactory and gustatory dysfunctions impose a significant burden yet lack the established treatment pathways and resources typical of other chronic conditions. The findings highlight an urgent need for increased awareness, investment in specialist services, and further research to develop effective treatments and improve outcomes for this frequently overlooked patient group.
Key Points
- Smell and taste disorders are increasingly prevalent but underrecognised.
- They substantially affect quality of life across physical, social, and psychological domains.
- Effective therapeutic options remain limited.
- Quality-of-life and depression scores for SATD patients are comparable to those for other chronic conditions.
- Further research and improved clinical services are essential to address this unmet need.
Conflicts of Interest
Carl Philpott is Associate Editor of the journal and a co-author of the reviewed article. The other authors declare no conflicts of interest.